Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The prognostic value and molecular landscape of human epidermal growth factor receptor 2 (HER2) low-expressing (HER2-L) metastatic colorectal cancer (mCRC) remain unclear. PATIENTS AND METHODS: This study enrolled patients with mCRC who had undergone surgical resection of primary tumor. Using the specimen, we evaluated HER2 expression by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). HER2 positivity was defined as follows: HER2 positivity (HER2-Pos) as IHC 3 + or IHC 2+/FISH positive, HER2-L as IHC 2+/FISH negative or IHC 1+, and HER2 negativity (HER2-Neg) as IHC 0+. Gene alterations were determined by next-generation sequencing. RESULTS: Between 2005 and 2015, a total of 370 patients were analyzed, comprising 15 patients (4%) with HER2-Pos, 21 (6%) with HER2-L, and 334 (90%) with HER2-Neg disease. The clinicopathologic characteristics among groups had no differences. HER2-L had a significantly higher proportion of coaltered RAS mutation than HER2-Pos (P = .037). With a median follow-up of 101.8 months, HER2-L had a significantly better median overall survival than HER2-Pos (P = .029) (18.2 months in HER2-Pos vs. 33.3 in HER2-L vs. 27.9 in HER2-Neg). In 58 patients harboring wild-type RAS and receiving anti-EGFR antibody therapy, HER2-L had a better median progression-free survival tendency than HER2-Pos, with 2.2 months in HER2-Pos, 7.8 in HER2-L, and 5.1 in HER2-Neg (P = .036). CONCLUSION: HER2-L mCRC showed a better prognosis than HER2-Pos mCRC, and it is similar to HER2-Neg mCRC. Hence, HER2-L mCRC might have different biologic behavior in terms of prognostic value and molecular landscape of mCRC, suggesting the possibility of implementation of HER2-guided clinical development against HER2-expressing mCRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
RAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016
Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939
Meric-Bernstam, F., Hurwitz, H., Raghav, K. P. S., McWilliams, R. R., Fakih, M., VanderWalde, A., Swanton, C., Kurzrock, R., Burris, H., Sweeney, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30904-5 · Cited by 573
Fakih, M., O'Neil, B., Price, T. J., Falchook, G. S., Desai, J., Kuo, J., Govindan, R., Rasmussen, E., Morrow, P. K. H., Ngang, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.3003 · Cited by 172
Siena, S., Di Bartolomeo, M., Raghav, K. P. S., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Fakih, M., Elez, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4000 · Cited by 54
Self-citation
Cited by
Yoshino, T., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Wainberg, Z., Elez, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38032-4 · Cited by 178
Self-citationBekaii-Saab, T. S., Lach, K., Hsu, L.-I., Siadak, M., Stecher, M., Ward, J., Beckerman, R., & Strickler, J. H. (2023) · The Oncologist · doi:10.1093/oncolo/oyad200 · Cited by 36
Babkoff, A., Zick, A., Hubert, A., Tarantino, P., & Grinshpun, A. (2024) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2023.100032 · Cited by 14
“65 In their research, they conducted an analysis of 370 patients with mCRC in Japan, revealing that the proportion of HER2-low tumors was 6%.”
Vaghi, C., Tosi, F., Mauri, G., Bonazzina, E., Amatu, A., Bencardino, K., Piscazzi, D., Roazzi, L., Villa, F., Maggi, M., et al. (2026) · Drugs · doi:10.1007/s40265-025-02253-2 · Cited by 11
Metadata
- Authors
- Yagisawa, M., Sawada, K., Nakamura, Y., Fujii, S., Yuki, S., Komatsu, Y., Yoshino, T., Sakamoto, N., & Taniguchi, H.
- Venue
- Clinical Colorectal Cancer
- Publisher
- Elsevier BV
- Published
- 2021-06
- Volume
- 20
- Issue
- 2
- Pages
- 113-120.e1
- ISSN
- 1533-0028 (ISSN-L)
- OpenAlex
- W3099718159
- Cited by
- 35
- References
- 7
- FWCI
- 1.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer. https://app.cochat.ai/papers/10.1016/j.clcc.2020.11.002
- The paper
- Yagisawa, M., Sawada, K., Nakamura, Y., Fujii, S., Yuki, S., Komatsu, Y., Yoshino, T., Sakamoto, N., & Taniguchi, H. (2021). Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2020.11.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.